A Phase 3 interventional study of Bosentan and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
This study's enrollment of 616 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Browse Idiopathic Pulmonary Fibrosis studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg b.i.d. (if body weight \< 40 kg)
Drug: Bosentan
Subjects receive placebo matching the bosentan treatment regimen
Drug: Placebo
Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
Also known as: Ro 47-0203, ACT-050088
Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
Time to Occurrence of Disease Worsening or Death up to End of Study.
Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).
Time frame: 36 months
Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.
Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).
Time frame: 12 months
| Milestone | Placebo | Bosentan |
|---|---|---|
| Started | 209 | 407 |
| Completed | 209 | 407 |
| Not completed | 0 | 0 |
Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).
| participants with event | Placebo | Bosentan |
|---|---|---|
| month 4 (122 days) | 10 | 18 |
| month 8 (244 days) | 22 | 40 |
| month12 (366 days) | 43 | 74 |
| month 18 (549 days) | 74 | 117 |
| month 24 (732 days) | 88 | 145 |
| month 30 (915 days) | 94 | 156 |
| month 36 (1098 days) | 94 | 158 |
Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).
| percentage of participants with event | Placebo | Bosentan |
|---|---|---|
| Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year. | 23.9 (18.3 to 30.3) | 19.9 (16.1 to 24.1) |
Collected over All treatment-emergent adverse events occurring after the start of study treatment and within 24 hours after the end of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 74/209 (35.4%) | 200/209 (95.7%) |
| Bosentan | — | 129/406 (31.8%) | 386/406 (95.1%) |
| Event | Placebo | Bosentan |
|---|---|---|
| IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders | 17/209 | 41/406 |
| PNEUMONIAInfections and infestations | 10/209 | 16/406 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 5/209 | 7/406 |
| ANGINA PECTORISCardiac disorders | 4/209 | 0/406 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/209 | 6/406 |
| CORONARY ARTERY DISEASECardiac disorders | 1/209 | 6/406 |
| BRONCHITISInfections and infestations | 3/209 | 2/406 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/209 | 0/406 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 3/209 | 1/406 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/209 | 3/406 |
| Event | Placebo | Bosentan |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 59/209 | 114/406 |
| IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders | 59/209 | 92/406 |
| COUGHRespiratory, thoracic and mediastinal disorders | 51/209 | 78/406 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 24/209 | 57/406 |
| BRONCHITISInfections and infestations | 28/209 | 44/406 |
| FATIGUEGeneral disorders | 15/209 | 46/406 |
| OEDEMA PERIPHERALGeneral disorders | 23/209 | 37/406 |
| HEADACHENervous system disorders | 22/209 | 44/406 |
| NASOPHARYNGITISInfections and infestations | 22/209 | 40/406 |
| SINUSITISInfections and infestations | 18/209 | 38/406 |
| Age, Continuous(years) | Placebo | Bosentan | Total |
|---|---|---|---|
| Mean | 63.2 ± 9.1 | 63.8 ± 8.4 | 63.6 ± 8.6 |
| Age, Customized(participants) | Placebo | Bosentan | Total |
|---|---|---|---|
| Between 18 and 40 years | 4 | 5 | 9 |
| Between 41 and 60 years | 74 | 119 | 193 |
| Between 61 and 70 years | 87 | 195 | 282 |
| > 70 years | 44 | 88 | 132 |
| Sex: Female, Male(Participants) | Placebo | Bosentan | Total |
|---|---|---|---|
| Female | 76 | 111 | 187 |
| Male | 133 | 296 | 429 |
| Region of Enrollment(participants) | Placebo | Bosentan | Total |
|---|---|---|---|
| United States | 99 | 185 | 284 |
| Serbia | 2 | 0 | 2 |
| Spain | 7 | 15 | 22 |
| Ireland | 2 | 2 | 4 |
| Austria | 3 | 4 | 7 |
| Israel | 7 | 16 | 23 |
| Switzerland | 5 | 8 | 13 |
| Italy | 8 | 14 | 22 |
| United Kingdom | 3 | 7 | 10 |
| France | 9 | 14 | 23 |
| Czech Republic | 5 | 9 | 14 |
| Canada | 14 | 30 | 44 |
| Belgium | 1 | 2 | 3 |
| Croatia | 0 | 2 | 2 |
| Australia | 11 | 22 | 33 |
| Germany | 10 | 26 | 36 |
| Netherlands | 0 | 2 | 2 |
| Japan | 14 | 26 | 40 |
| Korea, Republic of | 9 | 23 | 32 |
No study locations are listed for this record.
The record gives a start of Feb 2007, a primary completion of Feb 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 2 years 3 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Idiopathic Pulmonary Fibrosis →